Crosson T, Bhat S, Wang J, Salaun C, Fontaine E, Roversi K
bioRxiv. 2024; .
PMID: 39345572
PMC: 11429693.
DOI: 10.1101/2023.01.26.525731.
Anannya O, Huang W, August A
Sci Signal. 2024; 17(846):eadh2381.
PMID: 39042726
PMC: 11445781.
DOI: 10.1126/scisignal.adh2381.
Shi X, Liao T, Chen Y, Chen J, Liu Y, Zhao J
Arch Pharm Res. 2024; 47(7):632-644.
PMID: 38977652
DOI: 10.1007/s12272-024-01505-1.
Schwartz J, Capistrano K, Gluck J, Hezarkhani A, Naqvi A
Rev Med Virol. 2024; 34(3):e2543.
PMID: 38782605
PMC: 11260190.
DOI: 10.1002/rmv.2543.
Jiang B, Weinstock D, Donovan K, Sun H, Wolfe A, Amaka S
Cell Chem Biol. 2023; 30(4):383-393.e6.
PMID: 37015223
PMC: 10151063.
DOI: 10.1016/j.chembiol.2023.03.007.
ASK120067 potently suppresses B-cell or T-cell malignancies and by inhibiting BTK and ITK.
Song P, Bai G, Chan S, Zhang T, Tong L, Su Y
Front Pharmacol. 2023; 13:1071114.
PMID: 36588692
PMC: 9799096.
DOI: 10.3389/fphar.2022.1071114.
MicroRNA-155 acts as an anti-inflammatory factor in orbital fibroblasts from Graves' orbitopathy by repressing interleukin-2-inducible T-cell kinase.
Choi Y, Kim C, Choi E, Lee S, Chae M, Jun H
PLoS One. 2022; 17(8):e0270416.
PMID: 35980936
PMC: 9387810.
DOI: 10.1371/journal.pone.0270416.
Combination Approaches to Target PD-1 Signaling in Cancer.
Moore E, Strazza M, Mor A
Front Immunol. 2022; 13:927265.
PMID: 35911672
PMC: 9330480.
DOI: 10.3389/fimmu.2022.927265.
Analysis of Sepsis Markers and Pathogenesis Based on Gene Differential Expression and Protein Interaction Network.
Liang J, Wu W, Wang X, Wu W, Chen S, Jiang M
J Healthc Eng. 2022; 2022:6878495.
PMID: 35190763
PMC: 8858053.
DOI: 10.1155/2022/6878495.
A Novel Immune and Stroma Related Prognostic Marker for Invasive Breast Cancer in Tumor Microenvironment: A TCGA Based Study.
Huang Y, Chen L, Tang Z, Min Y, Yu W, Yang G
Front Endocrinol (Lausanne). 2021; 12:774244.
PMID: 34867821
PMC: 8636929.
DOI: 10.3389/fendo.2021.774244.
Possible Therapeutic Strategy Involving the Purine Synthesis Pathway Regulated by ITK in Tongue Squamous Cell Carcinoma.
Onidani K, Miura N, Sugiura Y, Abe Y, Watabe Y, Kakuya T
Cancers (Basel). 2021; 13(13).
PMID: 34283052
PMC: 8269312.
DOI: 10.3390/cancers13133333.
Targeting SLP76:ITK interaction separates GVHD from GVL in allo-HSCT.
Mammadli M, Huang W, Harris R, Xiong H, Weeks S, May A
iScience. 2021; 24(4):102286.
PMID: 33851101
PMC: 8024657.
DOI: 10.1016/j.isci.2021.102286.
Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis.
Lechner K, Neurath M, Weigmann B
J Mol Med (Berl). 2020; 98(10):1385-1395.
PMID: 32808093
PMC: 7524833.
DOI: 10.1007/s00109-020-01958-z.
Analysis of prognostic genes in the tumor microenvironment of lung adenocarcinoma.
Xu Z, Zhao M, Chen W, Li K, Qin F, Xiang W
PeerJ. 2020; 8:e9530.
PMID: 32775050
PMC: 7382940.
DOI: 10.7717/peerj.9530.
ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma.
Liu Y, Wang X, Deng L, Ping L, Shi Y, Zheng W
Cancer Cell Int. 2019; 19:32.
PMID: 30814910
PMC: 6376795.
DOI: 10.1186/s12935-019-0754-9.
Identification of inactive conformation-selective interleukin-2-inducible T-cell kinase (ITK) inhibitors based on second-harmonic generation.
Hantani Y, Iio K, Hantani R, Umetani K, Sato T, Young T
FEBS Open Bio. 2018; 8(9):1412-1423.
PMID: 30186743
PMC: 6120236.
DOI: 10.1002/2211-5463.12489.
Nonreceptor tyrosine kinases ITK and BTK negatively regulate mast cell proinflammatory responses to lipopolysaccharide.
Huang W, Morales J, Gazivoda V, August A
J Allergy Clin Immunol. 2015; 137(4):1197-1205.
PMID: 26581914
PMC: 5730405.
DOI: 10.1016/j.jaci.2015.08.056.
A Small Molecule Inhibitor of ITK and RLK Impairs Th1 Differentiation and Prevents Colitis Disease Progression.
Cho H, Shin H, Haberstock-Debic H, Xing Y, Owens T, Funk J
J Immunol. 2015; 195(10):4822-31.
PMID: 26466958
PMC: 4635571.
DOI: 10.4049/jimmunol.1501828.
Targets for Ibrutinib Beyond B Cell Malignancies.
Berglof A, Hamasy A, Meinke S, Palma M, Krstic A, Mansson R
Scand J Immunol. 2015; 82(3):208-17.
PMID: 26111359
PMC: 5347933.
DOI: 10.1111/sji.12333.
Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694.
Zhong Y, Dong S, Strattan E, Ren L, Butchar J, Thornton K
J Biol Chem. 2015; 290(10):5960-78.
PMID: 25593320
PMC: 4358234.
DOI: 10.1074/jbc.M114.614891.